• Citer

Utilisation des donneurs alternatifs avant allogreffe de cellules souches hématopoïétiques dans les hémopathies lymphoïdes : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC).

par Gauthier, Jean-Louis ;Chantepie, Sylvain;Bouabdallah, Krimo;Jost, Edgar;Nguyen, Stéphanie;Gac, Anne-Claire;Damaj, Gandhi;Duléry, Rémy;Michallet, Mauricette;Delage, Jérémy;Lewalle, Philippe ;Morschhauser, Franck;Salles, Gilles;Yakoub-Agha, Ibrahim;Cornillon, Jérôme
Référence Bulletin du cancer, 104, 12S, page (S106-S111)
Publication Publié, 2017-12

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Résumé :

Despite great improvements in the outcome of patients with lymphoma, some may still relapse or present with primary refractory disease. In these situations, allogeneic haematopoietic cell transplantation (allo-HCT) is a potentially curative option, in particular in the case of relapse after autologous stem cell transplantation. Recently, novel agents such as anti-PD1 and BTK inhibitors have started to challenge the use of allo-HCT for relapsed or refractory lymphoma. During the 2016 annual workshop of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC), we performed a comprehensive review of the literature published in the last 10 years and established guidelines to clarify the indications and transplant modalities in this setting. This manuscript reports on general considerations regarding allo-HCT for lymphoma and elaborates on the use of alternative donors in this setting.